Literature DB >> 9357448

Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome.

B C Jacobs1, H P Endtz, F G van der Meché, M P Hazenberg, M A de Klerk, P A van Doorn.   

Abstract

In this study we characterized the IgG antibodies against lipopolysaccharides (LPS) of Campylobacter jejuni in serum from patients with Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), C. jejuni enteritis and normal controls. In patients with GBS and MFS long-lasting titers of IgG1 and IgG3 antibodies against LPS from GBS and MFS associated C. jejuni were found. The subclass and course of these antibodies were highly associated with those of antibodies against GM1 and GQ1b in GBS and MFS patients. However, in C. jejuni enteritis and normal controls anti-LPS antibodies were predominantly IgG2. Antibody binding with LPS was reduced after treatment with choleratoxin and sialidases, suggesting that the ganglioside-like epitopes in LPS are immunodominant. These results further indicate that antecedent C. jejuni infections determine the specificity and isotype of anti-ganglioside antibodies in GBS and MFS patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357448     DOI: 10.1016/s0165-5728(97)00110-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective.

Authors:  Graham M O'Hanlon; Roland W M Bullens; Jaap J Plomp; Hugh J Willison
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

3.  Host factors determine anti-GM1 response following oral challenge of chickens with Guillain-Barré syndrome derived Campylobacter jejuni strain GB11.

Authors:  C Wim Ang; Jeroen R Dijkstra; Marcel A de Klerk; Hubert Ph Endtz; Pieter A van Doorn; Bart C Jacobs; Suzan H M Jeurissen; Jaap A Wagenaar
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

4.  Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma.

Authors:  Jonathan J D Baird-Gunning; Dinushi Weerasinghe; Matthew Silsby; Yash Gawarikar; Matteo S Carlino; Jessica L Smith; Steve Vucic
Journal:  Neurohospitalist       Date:  2018-05-27

5.  Characterization of human bactericidal antibodies to Bordetella pertussis.

Authors:  A A Weiss; P S Mobberley; R C Fernandez; C M Mink
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.

Authors:  C W Ang; J D Laman; H J Willison; E R Wagner; H P Endtz; M A De Klerk; A P Tio-Gillen; N Van den Braak; B C Jacobs; P A Van Doorn
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

7.  Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies.

Authors:  Zhahirul Islam; Michel Gilbert; Quazi D Mohammad; Kevin Klaij; Jianjun Li; Wouter van Rijs; Anne P Tio-Gillen; Kaisar A Talukder; Hugh J Willison; Alex van Belkum; Hubert P Endtz; Bart C Jacobs
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

8.  Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits.

Authors:  C W Ang; P G Noordzij; M A de Klerk; H P Endtz; P A van Doorn; J D Laman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.